Compugen Fourth Quarter and Yearend 2016 Conference Call Scheduled for Wednesday, February 15, 2017 at 10:00 AM EST

Monday, January 30, 2017 General News
Email Print This Page Comment
Font : A-A+

HOLON, Israel, January 30, 2017 /PRNewswire/ --

Compugen Ltd. (NASDAQ: CGEN), a leading

predictive drug discovery company, today announced that the Company will host a conference call on Wednesday, February 15, 2017 at 10:00 AM EST to review fourth quarter and yearend 2016 results.
Compugen participants on the conference call will include Martin Gerstel, Chairman; Dr. Anat Cohen-Dayag, President and CEO; and Ari Krashin, CFO. The quarterly and yearend results will be released on the Company's website (http://www.cgen.com) prior to the call.

To access the conference call, please dial 1-888-668-9141 from the US, or +972-3-9180609 internationally. The call will also be available via live webcast through Compugen's website, located at the following link.

A replay of the conference call will be available approximately two hours after the completion of the live conference call. To access the replay, please dial 1-888-326-9310 from the US or +972-3-9255904 internationally. The replay will be available through February 18, 2017.

About Compugen 

Compugen is a leading therapeutic discovery company utilizing its broadly applicable predictive discovery infrastructure to identify novel drug targets and develop first-in-class biologics. The primary focus of the Company's current pipeline is on immune checkpoint target candidates discovered by the Company, potentially providing the basis for a next wave of therapeutics for cancer immunotherapy. Compugen's business model is based on selectively entering into collaborations for its novel target candidates and drug product candidates at various stages of research and development under revenue-sharing agreements. The Company is headquartered in Israel, with R&D facilities in Israel and South San Francisco. At the US facilities, monoclonal antibody therapeutic candidates are discovered and developed against the Company's novel target candidates. For additional information, please visit Compugen's corporate website at http://www.cgen.com.

Company contact: Susanna Chau Director, Investor Relations and Corporate Communications Compugen Email: susannac@cgen.com Tel: +1-(650)-263-7001

SOURCE Compugen Ltd.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook